What records are connected here?
- Evidence lanes
- 2
- Source years
- 6
- Drugs@FDA applications
- 0
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
In clinical trials3,4Evidence: Smaller human trialsGut and digestion
Glepaglutide is a synthetic, long-acting analogue of glucagon-like peptide-2 (GLP-2), a gut hormone, with a chain of six lysines added at one end.3,4 It is being developed for short bowel syndrome with intestinal failure. In a randomized, placebo-controlled Phase 3 trial of 106 patients, one of the two glepaglutide groups reduced the need for parenteral support, nutrition and fluids that bypass the gut, more than placebo; the other did not.4 No FDA approval is reported in the sources reviewed here, and glepaglutide is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.3,7
| What it is | A modified GLP-2 analogue with several amino-acid substitutions and a C-terminal hexa-lysine, recorded as glepaglutide in FDA’s substance registry.3 |
|---|---|
| FDA status | Not FDA-approved. None of the sources reviewed here reports an approval of glepaglutide.3,4 |
| Human evidence | One randomized, double-blind, placebo-controlled Phase 3 trial in 106 patients with short bowel syndrome, published in 2025.4 |
| Evidence strength | Smaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned |
Glepaglutide is a synthetic peptide based on human GLP-2, with amino-acid substitutions and six lysines added at the end, according to FDA’s substance registry.3
The trial authors describe it as a long-acting GLP-2 analogue developed to improve how the intestine absorbs nutrients and fluid in people with short bowel syndrome.4
In the Phase 3 trial, 106 patients with short bowel syndrome who needed parenteral support at least three days a week were randomized to one of two glepaglutide groups or placebo for 24 weeks.4
In one glepaglutide group, weekly parenteral support volume fell more than with placebo, and more patients reached a 20% reduction (65.7% versus 38.9%); five patients were weaned off it entirely. The other group did not differ significantly from placebo.4
ClinicalTrials.gov lists the 2025 trial (NCT03690206) as completed, and a further Phase 3 trial in short bowel syndrome (NCT07197944) as recruiting in its September 29, 2026 record.1,2
Evidence-strength label: Smaller controlled human trials. How this label is assigned
None of the sources reviewed here reports an approval of glepaglutide by FDA.3,4
Glepaglutide remains in clinical trials: a Phase 3 registration (NCT07197944) is listed as recruiting in its September 29, 2026 record.1
FDA’s compounding safety-risk page, current as of April 22, 2026, does not list glepaglutide.5
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Glepaglutide is not among them.6,7
Its effects beyond 24 weeks, and why only one of the two glepaglutide groups separated from placebo, which the trial report does not settle.4
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Glepaglutide: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Glepaglutide are a bounded selection, not every registration or paper about Glepaglutide. For the years before Glepaglutide was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Glepaglutide as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Glepaglutide in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
In clinical trials; not FDA-approved. In a randomized, placebo-controlled Phase 3 trial of 106 patients, one of two glepaglutide groups reduced parenteral support needs. Glepaglutide is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗
Status sources checked through November 14, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
In clinical trials; not FDA-approved. In a randomized, placebo-controlled Phase 3 trial of 106 patients, one of two glepaglutide groups reduced parenteral support needs. Glepaglutide is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗
The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Clinical trials · source date September 29, 2026
ClinicalTrials.gov record NCT07197944↗Added to PeptideScanner November 16, 2026Clinical trials · added November 16, 2026
ClinicalTrials.gov record NCT07197944↗Source date September 29, 2026Clinical trials · added November 16, 2026
ClinicalTrials.gov record NCT03905707↗Source date September 8, 2026Clinical trials · added November 16, 2026
ClinicalTrials.gov record NCT04881825↗Source date September 8, 2026PeptideScanner currently has no selected regulatory records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
8 of 8 selected trial records include at least one phase value; 8 of 8 include a status value in the retained structured contract.
1 of 1 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PeptideScanner retained ClinicalTrials.gov record NCT03279302 at 2026-11-16T01:46:56.290Z. Its registry update date was 2017-12-22, and PeptideScanner's reviewed identity mapping was glepaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT03690206 at 2026-11-16T01:46:56.290Z. Its registry update date was 2025-07-17, and PeptideScanner's reviewed identity mapping was glepaglutide.
PeptideScanner retained ClinicalTrials.gov record NCT03905707 at 2026-11-16T01:46:56.290Z. Its registry update date was 2026-09-08, and PeptideScanner's reviewed identity mapping was glepaglutide.
1 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Selected records span December 22, 2017 to September 29, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07197944 at 2026-11-16T01:46:56.290Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was glepaglutide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03905707 at 2026-11-16T01:46:56.290Z. Its registry update date was 2026-09-08, and PeptideScanner's reviewed identity mapping was glepaglutide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04881825 at 2026-11-16T01:46:56.290Z. Its registry update date was 2026-09-08, and PeptideScanner's reviewed identity mapping was glepaglutide.↗
Literature metadata
PubMed lists PMID 41816796 in Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, Multicenter Study, with publication-date metadata of 2026-03-12 (day precision). PeptideScanner associated the retained record with the identity slug glepaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03690206 at 2026-11-16T01:46:56.290Z. Its registry update date was 2025-07-17, and PeptideScanner's reviewed identity mapping was glepaglutide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04991311 at 2026-11-16T01:46:56.290Z. Its registry update date was 2024-11-22, and PeptideScanner's reviewed identity mapping was glepaglutide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04318743 at 2026-11-16T01:46:56.290Z. Its registry update date was 2021-07-14, and PeptideScanner's reviewed identity mapping was glepaglutide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04178447 at 2026-11-16T01:46:56.290Z. Its registry update date was 2020-11-18, and PeptideScanner's reviewed identity mapping was glepaglutide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03279302 at 2026-11-16T01:46:56.290Z. Its registry update date was 2017-12-22, and PeptideScanner's reviewed identity mapping was glepaglutide.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
ClinicalTrials.gov · Official source · Source checked November 16, 2026
ClinicalTrials.gov · Official source · Source checked November 16, 2026
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
Gastroenterology · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026